ReviewJournal of cardiovascular development and disease2025
Personalized Treatment of Patients with Coronary Artery Disease: The Value and Limitations of Predictive Models.
Review in Journal of cardiovascular development and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The effects of Traditional Chinese Medicine on cardiac function after percutaneous coronary intervention: a meta-analysis and systematic review.Frontiers in cardiovascular medicine · 2026Review
- Toward an integrated risk paradigm: personalizing antithrombotic therapy for coronary heart disease with gastrointestinal bleeding.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Risk prediction models are increasingly used in the management of coronary artery disease (CAD), with applications ranging from diagnostic stratification to prognostic assessment and therapeutic guidance. In the context of CAD and percutaneous coronary intervention, clinical decision-making often relies on risk scores to estimate the likelihood of ischemic and bleeding events and to tailor antithrombotic strategies accordingly. Traditional scores are derived from clinical, anatomical, procedural, and laboratory variables, and their performance is evaluated based on discrimination and calibration metrics. While many established models are simple, interpretable, and externally validated, their predictive ability is often moderate and may be limited by outdated derivation cohorts, overfitting, or lack of generalizability. Recent advances have introduced artificial intelligence and machine learning models that can process large, high-dimensional datasets and identify patterns not apparent through conventional methods, with the aim to incorporate complex data; however, they are not exempt from limitations and struggle with integration into clinical practice. Notably, ethical issues, such as equity in model application, over-stratification, and real-world implementation, are of critical importance. The ideal predictive model should be accurate, generalizable, and clinically actionable. This review aims at providing an overview of the main predictive models used in the field of CAD and to discuss methodological challenges, with a focus on strengths, limitations and areas of applicability of predictive models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.